A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for up to 34 weeks. During the study, participants will visit their study clinic several times.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ulcerative Colitis
- Crohn's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 2 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Takeda
- Last updated on ClinicalTrials.gov
- August 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Children's Hospital Of Orange County · Orange, CA
Michigan · 1
- Children's Hospital of Michigan · Detroit, MI
Oklahoma · 1
- The University of Oklahoma Health Sciences Center · Oklahoma City, OK
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.